Article
The SELECT-GCA study, looking at upadacitinib in GCA, anchored the ACR 2024 opening plenary for a reason - it is highly notable and badly needed.
All News
Article
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.
Article
Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.
Eric Dein
Tweet
Biosimilar changes
ASP outpacing reimbursement making not affordable to use
Working with CMS but needs further legislation to fix this
FDA may change interchangeability status for medications to no longer require switching studies
@ACRheumDC @RheumNow #ACR24 https://t.co/daYQJvsHRG
Eric Dein
Tweet
Regulatory update @ACRheumDC
Inflation Reduction
Planned decrease in 10 drug prices including ETN
Expect this may be gutted by new administration. Will follow and advocate for drug pricing
@RheumNow #ACR24 https://t.co/ZrcMaLD6tu
Eric Dein
Tweet
@LennMcD @ACRheumDC
Do policies affect medication access, costs, reimbursements, telehealth, or your life as a rheumatology provider or patients?
Contact - quick and easy!
https://t.co/TvMlXiIZQR
@RheumNow #ACR24 https://t.co/plnUtl7Kml https://t.co/lFGx7hzlKy
Eric Dein
Tweet
@LennMcD @ACRheumDC
Current congress (118th) - very tight margins, paralyzed by the ‘24 elections. Now in lame duck
Many ACR policies made into bills - PA, step rx, copay accumulator, workforce, loan repayment, incr Rx transparency
Needs to be passed into law
@RheumNow #ACR24 https://t.co/1elEUiUAmh
Antoni Chan MD (Prof)
Tweet
Managing DMARDs in pregnancy. Curbside consults by Lisa Sammaritano @RheumNow #ACR24 https://t.co/FQrLNz4yCz
Mike Putman
Tweet
Phase 2 DBRCT of daxdilimab, an immunoglobulin-like transcript 7 to target plasmacytoid dendritic cells
No difference in primary outcome... but kiiiinda looks like something there?
I dislike Phase 2's; should go straight to Phase 3 if able
#ACR24 @rheumnow Abstr#1542 https://t.co/osDWDskfnA
Mike Putman
Tweet
@KDAO2011 help me out here; what is the point of analyses like this?
NO difference in PROs comparing voclo vs plbo...
...but if you split by responder status its different
Prescribing the drug doesn't help PROs, but when it works it works? 🤔
#ACR @RheumNow Abstr#1538 https://t.co/339drHwUuK
Richard Conway
Tweet
This is very true. We showed a number of years ago that patients with gout have increased platelet activation at baseline, which then dramatically increases during flare. Treating gout properly may ameliorate this. #ACR24 @RheumNow https://t.co/VL8fy3ezjx https://t.co/9XdrG1NG9c
Brian Jaros, MD
Tweet
Factors associated w/ secukinumab response in PsA?
Analysis of 2.7k pt in EuroSpA
Associated w/ favorable response
❗️elevated CRP >10 mg/L
❗️fewer prev tx
Associated w/ lower response:
❗️smoking
❗️higher patient global score / HAQ
@RheumNow #ACR24 Abstr 2325
Brian Jaros, MD
Tweet
New data to guide role of long-term, low dose GC in GPA
Active GPA s/p tx -> randomized to d/c pred within 1 mo or stay on 5mg daily
Fewer relapses on 5mg pred but w/qualifications:
👉 most flares = minor
👉 no difference in flares if RTX on board
@RheumNow #ACR24 Abst 0774 https://t.co/Jvc40QWLqM
Richard Conway
Tweet
Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) and colchicine (HR 0.82). I worry about the discordant rates, ULT initiation much lower. @RheumNow #ACR24 Abstr#0848 https://t.co/VTKHMmDEKV https://t.co/C2opiDmBXx
Mrinalini Dey
Tweet
🤵♂️Results from BACHELOR
➡️34 PMR pts
➡️18 BARI, 16 PBO
➡️Primary endpoint: CRP PMR-AS≤10 w/o oral GC rescue from W0 to 12
78% BARI pts reached primary endpoint vs 13% PBO
No new safety signals
BARI 4mg 12W, then 2mg 12W➡️36W low disease activity in PMR
Ab0858 #ACR24 @RheumNow
Mrinalini Dey
Tweet
How does #cardiovascular risk vary with #ACPA & #biologics in #RA?
⬆️BMI assoc with ⬆️MACE risk in ACPA+ pts
In ACPA- pts, BMI inversely assoc with MACE risk among pts on biologics
Further evidence to consider ACPA, BMI & MACE as part of RA management
Ab0870 #ACR24 @RheumNow https://t.co/UkkC146DWS
Richard Conway
Tweet
Hamroun et al. Meta-analysis of glucocorticoids in pregnancy and breast-feeding. Increase pre-term birth with GCs, adjusted OR 2.24. Dose-dependent effect. Minimal breastmilk transfer. @RheumNow #ACR24 Abstr#0810 https://t.co/H0o9ElsHmc https://t.co/uciFP6UOhF
Eric Dein
Tweet
Cannabis in Pain:
CBD can help with nociceptive pain
THC better for neuropathic, centralized pain
Perhaps a role in helping decrease other medications like opiates
Clauw 16S18
#ACR24 @RheumNow https://t.co/kaQXrD4GAn
Akhil Sood MD
Tweet
Abstract #0805
Data from OTIS Registry shows Certolizumab pegol (Cimzia) exposure during pregnancy was not associated with increased risk of major birth defects, structural defects, or adverse pregnancy outcomes. #ACR24 @RheumNow
Akhil Sood MD
Tweet
Is it safe to administer rotavirus vaccine to infants exposed in utero to TNFi?
Abstract#0806 shows no significant ↑ in the risk of diarrhea-related healthcare events among TNFi-exposed infants who received the vaccine compared to those who did not
@RheumNow #ACR24 https://t.co/HpTCgywE4H
